

PRODUCT INFORMATION



ER-819762

Item No. 10531

CAS Registry No.: 1155773-15-1
Formal Name: (10S)-1'-[(3,5-dimethylphenyl)methyl]-2-ethyl-5,10-dihydro-7,9-dimethoxy-10-methyl-spiro[1H-imidazo[1,5-b][2]benzazepine-1,4'-piperidin]-3(2H)-one

MF: C₃₀H₃₉N₃O₃


FW: 489.7

Purity: ≥98%

Supplied as: A solid

Storage: -20°C

Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

ER-819762 is supplied as a solid. A stock solution may be made by dissolving the ER-819762 in the solvent of choice, which should be purged with an inert gas. ER-819762 is soluble in the organic solvent DMSO at a concentration of approximately 50 mg/ml.

Description

ER-819762 is an antagonist of the prostaglandin E₂ (PGE₂; Item No. 14010) receptor subtype EP₄ (IC₅₀ = 70 nM).¹ It is selective for EP₄ over EP₁, EP₂, and EP₃ in a cAMP reporter assay at 10 μM. ER-819762 reduces differentiation of mouse helper T cells when used at concentrations ranging from 0.1 to 10 nM and decreases IL-23 secretion by mouse dendritic cells from 0.04 to 5 nM. It also reduces the levels of Marek's disease virus (MDV) in chicken embryonic fibroblasts (CEFs) when used at a concentration of 1 μM.² Oral administration of ER-819762 (30 and 100 mg/kg) prevents and reverses paw swelling, edema, and inflammation in a mouse model of rheumatoid arthritis induced by glucose-6-phosphate isomerase (GPI).¹

References

1. Chen, Q., Muramoto, K., Masaaki, N., *et al.* A novel antagonist of the prostaglandin E₂ EP₄ receptor inhibits Th1 differentiation and Th17 expansion and is orally active in arthritis models. *Br. J. Pharmacol.* **160**(2), 292-310 (2010).
2. Boodhoo, N., Kamble, N., Kaufer, B.B., *et al.* Replication of Marek's disease virus is dependent on synthesis of *de novo* fatty acid and prostaglandin E₂. *J. Virol.* **93**(13), e00352-19 (2109).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 03/01/2023

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM